Gilead Sciences, Inc. (NASDAQ:GILD) was active yesterday as one Bloomberg reporter thinks he has another take on the recent Waxman letter. Drew Armstrong — via his own Twitter account — said Gilead execs had a meeting scheduled with Waxman all along and the letter just seemed like Waxman was making an effort to drag them in. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was 3.37% in last session and finished the day at $70.86. Traded volume was 18.59million shares in the last session and the average volume of the stock remained 13.01million shares. The beta of the stock remained 0.55. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced last week that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (:NSCLC) in patients who had previously been treated with Pfizer’s Xalkori. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 1.00 percent to $8.06 Monday on volume of 9.01million shares. The intra-day range of the stock was $7.75 to $8.10. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.50billion.

Arena Pharmaceuticals (NASDAQ:ARNA) saw a significant decrease in short interest during the month of January. As of March 14th, there was short interest totalling 56,270,707 shares, a decrease of 3.1% from the February 28th total of 58,068,228 shares, Analyst Ratings News reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on Mar 31, 2014 reported a increase of 3.28% to the closing price of $6.30. Its fifty two weeks range is $4.05 -$9.25. The total market capitalization recorded $1.38billion. The overall volume in the last trading session was 5.88million shares. In its share capital, ARNA has 219.26million outstanding shares.

MannKind Corp.’s (MNKD – Analyst Report) shares were down more than 7% following the release of briefing documents ahead of an FDA advisory panel meeting where the company’s diabetes candidate, Afrezza (inhaled insulin) will be reviewed. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee meeting is scheduled for Apr 1. On Monday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -16.77% to close the day at $4.02. Company monthly performance is recorded as -35.06%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is -18.46%.